Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C31H36F6N6O2 |
Molecular Weight | 638.647 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1N=NC(=N1)N(CC2=CC(=CC(=C2)C(F)(F)F)C(F)(F)F)[C@H]3CCCN(C[C@H]4CC[C@@H](CC4)C(O)=O)C5=C3C=C(C)C=C5C
InChI
InChIKey=IHIUGIVXARLYHP-YBXDKENTSA-N
InChI=1S/C31H36F6N6O2/c1-18-11-19(2)27-25(12-18)26(5-4-10-42(27)16-20-6-8-22(9-7-20)28(44)45)43(29-38-40-41(3)39-29)17-21-13-23(30(32,33)34)15-24(14-21)31(35,36)37/h11-15,20,22,26H,4-10,16-17H2,1-3H3,(H,44,45)/t20-,22-,26-/m0/s1
Molecular Formula | C31H36F6N6O2 |
Molecular Weight | 638.647 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 22:10:37 UTC 2023
by
admin
on
Fri Dec 15 22:10:37 UTC 2023
|
Record UNII |
51XWV9K850
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
EVACETRAPIB
Created by
admin on Fri Dec 15 22:10:37 UTC 2023 , Edited by admin on Fri Dec 15 22:10:37 UTC 2023
|
PRIMARY | |||
|
DB11655
Created by
admin on Fri Dec 15 22:10:37 UTC 2023 , Edited by admin on Fri Dec 15 22:10:37 UTC 2023
|
PRIMARY | |||
|
C166804
Created by
admin on Fri Dec 15 22:10:37 UTC 2023 , Edited by admin on Fri Dec 15 22:10:37 UTC 2023
|
PRIMARY | |||
|
1186486-62-3
Created by
admin on Fri Dec 15 22:10:37 UTC 2023 , Edited by admin on Fri Dec 15 22:10:37 UTC 2023
|
PRIMARY | |||
|
SUB189015
Created by
admin on Fri Dec 15 22:10:37 UTC 2023 , Edited by admin on Fri Dec 15 22:10:37 UTC 2023
|
PRIMARY | |||
|
CHEMBL2017179
Created by
admin on Fri Dec 15 22:10:37 UTC 2023 , Edited by admin on Fri Dec 15 22:10:37 UTC 2023
|
PRIMARY | |||
|
DTXSID801026275
Created by
admin on Fri Dec 15 22:10:37 UTC 2023 , Edited by admin on Fri Dec 15 22:10:37 UTC 2023
|
PRIMARY | |||
|
100000174866
Created by
admin on Fri Dec 15 22:10:37 UTC 2023 , Edited by admin on Fri Dec 15 22:10:37 UTC 2023
|
PRIMARY | |||
|
51XWV9K850
Created by
admin on Fri Dec 15 22:10:37 UTC 2023 , Edited by admin on Fri Dec 15 22:10:37 UTC 2023
|
PRIMARY | |||
|
m5217
Created by
admin on Fri Dec 15 22:10:37 UTC 2023 , Edited by admin on Fri Dec 15 22:10:37 UTC 2023
|
PRIMARY | Merck Index | ||
|
XX-71
Created by
admin on Fri Dec 15 22:10:37 UTC 2023 , Edited by admin on Fri Dec 15 22:10:37 UTC 2023
|
PRIMARY | |||
|
9442
Created by
admin on Fri Dec 15 22:10:37 UTC 2023 , Edited by admin on Fri Dec 15 22:10:37 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
|
||
|
SOLVATE->ANHYDROUS | |||
|
TARGET -> INHIBITOR |
Evacetrapib did not impact aldosterone levels or blood pressure, even while achieving more substantial modulation of HDL and LDL levels than torcetrapib. Unfortunately, it also did not offer clinical benefit in terms of reducing CV events and has been discontinued.
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|